Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $60.64

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been assigned a consensus rating of “Buy” from the twelve analysts that are presently covering the firm, Marketbeat reports. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $60.73.

Several equities analysts have recently weighed in on MIRM shares. Raymond James reaffirmed a “strong-buy” rating on shares of Mirum Pharmaceuticals in a research note on Tuesday, May 13th. HC Wainwright restated a “buy” rating and set a $73.00 target price on shares of Mirum Pharmaceuticals in a report on Monday. Robert W. Baird lifted their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, February 27th. Finally, JMP Securities boosted their price target on shares of Mirum Pharmaceuticals from $74.00 to $76.00 and gave the stock a “market outperform” rating in a research report on Friday, May 9th.

Mirum Pharmaceuticals Stock Performance

MIRM opened at $45.34 on Wednesday. The business’s 50-day moving average price is $42.97 and its two-hundred day moving average price is $44.55. Mirum Pharmaceuticals has a 1 year low of $23.83 and a 1 year high of $54.23. The company has a market capitalization of $2.25 billion, a price-to-earnings ratio of -22.45 and a beta of 0.95. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.05. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company had revenue of $111.59 million during the quarter, compared to analysts’ expectations of $98.47 million. During the same period in the prior year, the firm earned ($0.54) earnings per share. Mirum Pharmaceuticals’s revenue for the quarter was up 61.2% compared to the same quarter last year. Equities analysts expect that Mirum Pharmaceuticals will post -1.43 EPS for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 57,606 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $44.35, for a total transaction of $2,554,826.10. Following the completion of the sale, the senior vice president now owns 4,841 shares of the company’s stock, valued at $214,698.35. This trade represents a 92.25% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Patrick J. Heron acquired 1,335 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was bought at an average price of $45.57 per share, for a total transaction of $60,835.95. Following the completion of the acquisition, the director now owns 163,643 shares of the company’s stock, valued at approximately $7,457,211.51. The trade was a 0.82% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 92,764 shares of company stock worth $4,109,161 in the last ninety days. Insiders own 14.36% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC grew its position in shares of Mirum Pharmaceuticals by 259.4% in the first quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares during the last quarter. Jones Financial Companies Lllp lifted its holdings in Mirum Pharmaceuticals by 100.0% during the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock worth $30,000 after purchasing an additional 357 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in Mirum Pharmaceuticals in the 4th quarter valued at $35,000. Comerica Bank boosted its stake in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after purchasing an additional 278 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new position in Mirum Pharmaceuticals in the 4th quarter valued at $42,000.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.